Alerting patients to ALL relapse risk

Israeli biotech Curewize successfully completed the clinical trial of its lead product ProALLBM on acute lymphoblastic leukemia (ALL) patients. ProALLBM reveals patients’ risk of relapse with just one bone marrow sample. They can then be given early treatment.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *